
From Data to Insights: Allucent's Expert Team Leverages MIDD to Deliver Efficient Drug Development Strategies



Principles

Let your data be your guide. With model-informed drug development (MIDD), you can leverage your existing data and others to optimize your pre-clinical and clinical studies and development programs.

MIDD uses mathematical and statistical models to:

- Design, select, justify, and optimize dose and regimen through all development phases
- Assess pre-clinical and clinical risks and compare outcome vs. target product profiles, competitors or standard of care.
- Design, simulate and analyze clinical trials to maximize the probability of success; optimize sample size, trial duration, sampling and assessment schedules, patient selection, and trial conditions.
- Support submission and labeling including dose and dose adjustments for special populations, drug-drug interactions, and contra-indications.

Allucent has an expert team of pharmacometricians and modelers with state-of-the-art high-performance computing (AWS) to help you design, simulate and analyze your drug development studies and programs.

Services

Translational MIDD

- Efficacious and FIH Dose Prediction
- In vitro/in vivo Translation
- Drug Interactions/IVIVC

Clinical MIDD

- Dose Selection and Justification
- Population PK or PK/PD
- Clinical Study Design & Simulation
- Dose or Exposure Response
- Interim and Final Trial Analysis
- Comparator/Competitor Profiling
- Concentration QT (cQT)
- Dataset Programming

Methodologies and computing

- Population Analysis (NLME)
- PBPK/QSP (PKSIM/Mobi)
- Allometric Scaling
- Validated Cloud High-performance Computing (NONMEM/R/Pirana/PSN)



